Dosing Regimen definition

Dosing Regimen. Phase A: Three inductions/week to test animals on single test site (nine total inductions) Phase B: Test animals challenged on new test site and challenge control animals dosed approximately 2 weeks after Induction 9 Phase C: Test animals rechallenged on a test site with naive rechallenge control animals dosed (if needed).
Dosing Regimen. A single daily dose for 14-days followed by a 7-Day recovery period. Route of Administration: Transdermal patch or subcutaneous dose administration. Test System: Number of Animals Group: Dose Males Females 1 Patch - Control 3 (2) 3 (2) 3 Patch - High 3 (2) 3 (2) ( ) animals will be held for 7-Day recovery Spares: 4 animals Total Population: 30 animals Age: Approximately 2.5 – 3.5 kg at receipt Source: Xxxxxxx River Pretreatment Period: Approximately 10 days.
Dosing Regimen. Phase A: Three inductions/week to test animals on single test site (nine total inductions) Phase B: Test animals challenged on new test site and challenge control animals dosed approximately 2 weeks after Induction 9 Phase C: Test animals rechallenged on a test site with naive rechallenge control animals dosed (if needed). Route of Administration: Dermal (skin painting) dose administration — 6 hour exposure Test System: Group Number of Animals Test/Placebo 10/10 Challenge Control 10 Rechallenge 10 DNCB Positive Control Test 10 Positive Control 10 Spares 5 animals Total Population 69 animals Age Approximately 7 weeks at receipt Source Xxxxxxx River Laboratories Pretreatment Period At least 5 days Mortality/Cageside Observations: Mortality/viability observations will be conducted on twice daily on all animals. Positive clinical observations only. Dermal scoring at 24 and 48 hours. Body Weight/Food Consumption: Body weights obtained at 3 intervals. Terminal Procedures: Animals terminated without necropsy Reporting: Audited draft report provided in approximately 4 weeks. Archiving: Archiving materials will be maintained through final report issuance. Date Created: October 2, 2009 Sponsor: Radius Title: A 14-Day Local Tolerance Study in Rabbits with a 7-Day Recovery Period Study Number: SSU00067 Xxxxxxx River Facility: Ohio Compliance: GLP Species/Strain: New Zealand White Rabbits Dose Formulation Preparation (assumes basic dose preparation): Test material to be dispensed as received; no samples obtained. Dose Formulation Analysis (assumes standard HPLC-UV method): N/A Dosing Regimen: A single daily dose for 14-days followed by a 7-Day recovery period. Route of Administration: Transdermal patch or subcutaneous dose administration. Test System: Number of Animals Group: Dose Males Females 1 Patch - Control 3 (2) 3 (2)

Examples of Dosing Regimen in a sentence

  • Dosing Regimen To reduce the risk of retinal toxicity, the recommended maximum dosing is 5mg/kg/day based on actual body weight, practically, this will be 200mg once daily or 200mg twice daily.

  • Dose Formulation Analysis (assumes standard HPLC-UV method): N/A Dosing Regimen: Once daily for 182 days (6 months).

  • Dose Formulation Analysis (assumes standard HPLC-UV method: N/A Dosing Regimen: Once daily for 7 days.

Related to Dosing Regimen

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Dose is a generic term that means absorbed dose, dose equivalent, effective dose equivalent, committed dose equivalent, committed effective dose equivalent, total organ dose equivalent, or total effective dose equivalent. For purposes of these regulations, "radiation dose" is an equivalent term.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • clinical evidence means clinical data and clinical evaluation results pertaining to a device of a sufficient amount and quality to allow a qualified assessment of whether the device is safe and achieves the intended clinical benefit(s), when used as intended by the manufacturer;

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or Condition and is described in any of the following:

  • Phase III Trial means a human Clinical Trial of the Licensed Product, which trial is designed (a) to establish that the Licensed Product is safe and efficacious for its intended use; (b) to define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; and (c) consistent with 21 CFR § 312.21(c).

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase IV Clinical Trial means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by BMS and that otherwise fit the foregoing definition.

  • Pivotal Clinical Trial means a pivotal human clinical trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Step therapy protocol means a protocol or program that establishes the specific

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Clinical evaluation means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Study means the investigation to be conducted in accordance with the Protocol.